# **PRODUCT** INFORMATION



Darunavir-d<sub>9</sub>

Item No. 2522Ó

CAS Registry No.: Formal Name:	1133378-37-6 (3R,3aS,6aR)-N-[(1S,2R)-3-[[(4-aminophenyl) sulfonyl][2-(methyl-d <sub>3</sub> )propyl-1,1,2,3,3,3-d <sub>6</sub> ]amino]-	
	2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid,	
	hexahydrofuro[2,3-b]furan-3-yl ester	
Synonym:	TMC114-d <sub>9</sub>	
MF:	$C_{27}H_{28}D_9N_3O_7S$	
FW:	556.7	
Chemical Purity:	≥98% (Darunavir)	NH <sub>2</sub>
Deuterium		
Incorporation:	≥99% deuterated forms (d <sub>1</sub> -d <sub>9</sub> ); ≤1% d <sub>0</sub>	
Supplied as:	A solid	D' I 'D D
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product exections. Datch exection and the product are provided on each cartificate of analysis		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

# Laboratory Procedures

Darunavir-do is intended for use as an internal standard for the quantification of darunavir (Item No. 15866 | 31083) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Darunavir-d<sub>o</sub> is supplied as a solid. A stock solution may be made by dissolving the darunavir-d<sub>o</sub> in the solvent of choice. Darunavir-d<sub>o</sub> is soluble in organic solvents such as methanol, DMSO, and dimethyl formamide, which should be purged with an inert gas.

## Description

Darunavir-do is intended for use as an internal standard for the quantification of darunavir (Item Nos. 15866 | 31083) by GC- or LC-MS. Darunavir is an HIV-1 protease inhibitor.<sup>1</sup> It is active against HIV-1<sub>LAI</sub> in MT-2 cells (IC<sub>50</sub> = 3 nM) with a cytotoxic concentration (CC<sub>50</sub>) of 74.4  $\mu$ M. Darunavir is also active against wild-type and multidrug-resistant clinical isolates of HIV-1 in phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs; IC<sub>50</sub>s = 3 and 3-29 nM, respectively). It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations (IC<sub>50</sub>s = 2.5 and 2.8 nM, respectively).<sup>2</sup> Formulations containing darunavir have been used in combination therapy for the treatment of HIV.

# References

- 1. Koh, Y., Nakata, H., Maeda, K., et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47(10), 3123-3129 (2003).
- 2. Titanji, B.K., Aasa-Chapman, M., Pillay, D., et al. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 10:161 (2013).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM